March 2, 2016

MorphoSys AG

Year End Results 2015 & Outlook 2016

Today on the Call

Dr. Simon Moroney

Chief Executive Officer

Jens Holstein

Chief Financial Officer

Dr. Marlies Sproll

Chief Scientific Officer

Dr. Arndt Schottelius

Chief Development Officer

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR

Safe Harbor

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

Content

- Proprietary Pipeline
- Partner Pipeline
- Financial Review 2015
- Financial Outlook
- Summary
- Q&A

Strong and Differentiated Biopharmaceutical Pipeline

Successful Transformation from Technology Provider to Drug Development Company

- First partnered programs approaching the market
- Proprietary portfolio is gaining momentum

Increasing Confidence in Proprietary Portfolio

- Additional resources
- Majority of spending for clinical programs

Long-term Strategy

- Growing portfolio of innovative therapeutics
- Creation of long-term, sustainable value

Content

- **Proprietary Pipeline**
- Partner Pipeline
- Financial Review 2015
- Financial Outlook
- Summary
- Q&A

MOR208
First- & Best-in Class Potential

MOR208

Updated phase 2 monotherapy data in NHL

First data from phase 2 combination trial MOR208 plus lenalidomide in CLL (IIT)

MOR208 - Differentiation

- Benign safety profile
- Long half-life in circulation
- Straightforward manufacturing
- Minor structural modification leads to significantly enhanced B cell depletion



MOR208 has the potential to become an important combination partner for the treatment of r/r DLBCL and Btk-inhibitor refractory CLL patients.

MOR208
Comprehensive Clinical Development Plan



Phase 2

Phase 2/3

IIT: Investigator-initiated trial

MOR202
A Differentiated Antibody for Multiple Myeloma

MOR202

Encouraging phase 1/2a data in r/r multiple myeloma

- MOR202
- MOR202 + lenalidomide
- MOR202 + pomalidomide

MOR202 - Differentiation

- Convenience: 2-hour infusion
- Best-in class infusion tolerability
- Preservation of NK cells



MOR202 is shaping up to be a genuine advance in the treatment of multiple myeloma, potentially offering patients superior outcomes and quality of life.

MOR209/ES414
A Novel Bi-specific Antibody for Prostate Cancer

MOR209/ES414

Co-development Agreement with Emergent BioSolutions

- Phase 1 clinical trial in mCRPC patients was started in March of 2015

Restructured Agreement with Emergent BioSolutions

- Adjustment of dosing regimen and administration
- Reduction of MorphoSys's cost sharing and reduced milestone payments



Clinical development will continue in 2016 under an adapted clinical development plan.

Early-stage Portfolio

Co-development with Galapagos

- Inflammatory program, novel mechanism-of-action
- Start of phase 1 in H1 of 2016
- Evaluation of safety and pharmacokinetics of the antibody in healthy volunteers and also in patients

Lanthipeptide from the Lanthio Pharma acquisition

- Agonist of the angiotensin II type 2 receptor
- Strong anti-fibrotic efficacy in pre-clinical models
- Start of phase 1 expected in Q4 of 2016

MOR103/GSK3196165
Anti-inflammatory Program Licensed to GSK

MOR103/ GSK3196165

License Agreement with GSK

- HuCAL antibody specific for GM-CSF
- Phase 2b study in RA (BAROQUE) ongoing
- Phase 2 in hand osteoarthritis to start in 2016



Powerful Technology Base Ensures Pipeline Sustainability

Innovative Targets

GPCRs, ion channels

HEPTARES therapeutics

G7 Therapeutics

Immune checkpoints

MERCK

MHC-presented, tumor-associated peptides

immatics

Source of novel targets

Universität Stuttgart

Proprietary Platforms

Antibody library

Ylanthia®

Protein optimization

SLONOMICS

Lantipeptides

lanthio pharma
a MorphoSys Company

Content

Proprietary Pipeline	**Partner Pipeline**	Financial Review 2015
Financial Outlook	Summary	Q&A

Bimagrumab (BYM338)
A Novartis Musculoskeletal Program

Bimagrumab

- HuCAL antibody specific for ActRIIB, antagonizes myostatin binding to muscle cells
- Development in muscle-wasting conditions
- FDA breakthrough therapy designation

Current Status

- Pivotal study in sIBM with 240 patients ongoing, phase 3 data expected in H1 2016
- Phase 2 studies in sarcopenia, cachexia and hip fracture surgery



Bimagrumab could become the first marketed product from our HuCAL technology platform

Guselkumab (CNTO1959)
A Janssen Anti-Inflammatory Program

Guselkumab

- A HuCAL antibody specific for IL-23, does not bind IL-12
- Being developed in psoriasis and psoriatic arthritis

Current Status

- Six Phase 3 clinical trials ongoing
- First Phase 3 data expected in 2016
- Anticipated filing in 2016



Guselkumab would then be the second marketed product based on the HuCAL technology and the second source of royalty-based income

Additional Late-stage Partner Programs

A Roche Alzheimer's Disease Program

- Higher doses will be tested
- Phase 2/3 (SCarlet RoAD) in prodromal Alzheimer's disease ongoing (open label extension)
- Phase 3 (Marguerite RoAD) in mild Alzheimer's disease ongoing (open label extension)

A Bayer Cancer Program

- Start of global phase 2 clinical trial in mesothelioma; a study designed to support registration
- ADC program targeting mesothelin-expressing cancer cell

The MorphoSys Pipeline
25 Clinical Product Candidates, 103 Total

Most advanced development stage

Program	Partner	Target	Disease Area	Discovery	Preclinic	Phase 1	Phase 2	Phase 3
Bimagrumab (BYM338)	Novartis	ActRIIB	sIBM (musculoskeletal)					
Guselkumab (CNTO1959)	Janssen	IL23p19	Psoriasis					
Gantenerumab	Roche	Amyloid-ß	Alzheimer's disease					
MOR208	-	CD19	ALL, CLL, NHL					
MOR202	-	CD38	Multiple myeloma					
MOR103/GSK3196165	GSK	GM-CSF	Inflammation					
Anetumab Ravtansine (BAY94-9343)	Bayer	Mesothelin (ADC)	Solid tumors					
BHQ880	Novartis	DKK-1	Multiple myeloma					
BPS804	Mereo/Novartis	Sclerostin	Brittle bone syndrome					
CNTO3157	Janssen	-	Inflammation					
CNTO6785	Janssen	-	Inflammation					
LFG316	Novartis	C5	Eye diseases					
LJM716	Novartis	HER3	Cancer					
Tarextumab (OMP-59R5)	OncoMed	Notch 2	Solid tumors					
VAY736	Novartis	BAFF-R	Inflammation					
MOR209/ES414	Emergent	PSMA/CD3	Prostate cancer					
BAY1093884	Bayer	TFPI	Hemophilia					
BI-836845	BI	IGF-1	Solid tumors					
NOV-7	Novartis	-	Eye diseases					
NOV-8	Novartis	-	Inflammation					
NOV-9	Novartis	-	Diabetic eye diseases					
NOV-10	Novartis	-	Cancer					
NOV-11	Novartis	-	Blood disorders					
PF-05082566	Pfizer	4-1BB	Solid tumors					
Vantictumab (OMP-18R5)	OncoMed	Fzd 7	Solid tumors					
MOR106	Galapagos	-	Inflammation					
MOR107 (LP2)	-	AT2-R	Fibrosis					
Immuno-oncology program	Merck Serono	-	Cancer					
Immuno-oncology program	Immatics	-	Cancer					
6 MOR programs	-	-	Various					

89 Partnered Discovery Programs
13 MOR Programs
1 Outlicensed Program

In addition, 25 partnered programs in pre-clinic, and 43 partnered programs in discovery

Content

Proprietary Pipeline	Partner Pipeline	**Financial Review 2015**
Financial Outlook	Summary	Q&A

Financial Highlights in 2015



in € million

Revenue and EBIT for 2015 contain a non-recurring contribution of approximately €59 million from the recognition of deferred revenues and a payment attributable to the early ending of the Celgene collaboration in March 2015.

FY2015: Income Statement

in € million*	2015	2014
Revenues	**106.2**	**64.0**
Research and Development Expenses	78.7	56.0
General & Administrative Expenses	15.1	14.1
Total Operating Expenses	**(93.7)**	**(70.1)**
Other Operating Income/(Expense)	4.7	0.2
EBIT	**17.2**	**(5.9)**
Finance Income	3.8	1.8
Finance Expenses	0.4	0.2
Income Tax (Expense)/Income	(5.7)	1.3
Consolidated Net Profit/(Loss)	**14.9**	**(3.0)**
Diluted Net Profit/(Loss) per Share (in €)	**0.57**	**(0.12)**

* Differences due to rounding

Segment Reporting

Proprietary Development



Partnered Discovery



FY2015: Balance Sheet

in € million*	Dec 31, 2015	Dec 31, 2014
Assets		
Cash and Cash Equivalents#	90.9	32.2
Available-for-sale Financial Assets#	64.3	106.1
Bonds, Available-for-sale#	33.1	7.5
Financial Assets classified as Loans & Receivables#	94.6	157.0
Other Current Assets	17.2	19.6
Total Current Assets	***300.1***	***322.4***
Financial Assets classified as Loans & Receivables, Net of Current Portion#	15.5	50.0
Total Non-current Assets	***100.0***	***104.1***
Total Assets	**400.1**	**426.5**
Liabilities & Stockholders' Equity		
Total Current Liabilities	***27.5***	***32.7***
Total Non-current Liabilities	***9.9***	***45.0***
Total Stockholders' Equity	**362.7**	**348.8**
Total Liabilities & Stockholders' Equity	**400.1**	**426.5**

As of Dec. 31, 2015, MorphoSys held liquid funds and marketable securities as well as other short-term and long-term financial assets in the amount of €298.4 million (Dec. 31, 2014: € 352.8 million)

* Differences due to rounding

Content

Proprietary Pipeline

Partner Pipeline

Financial Review 2015

Financial Outlook

Summary

Q&A

Financial Guidance 2016

in € million	2015A	Guidance 2016
Group Revenues	**106.2**	**47 to 52**
Proprietary R&D Expenses (incl. Technology Development)	56.6	76 to 83
EBIT	**17.2**	**-58 to -68**

Cash, cash equivalents & marketable securities as well as other short-term and long-term financial assets	298.4

Content

Proprietary Pipeline	Partner Pipeline	Financial Review 2015
Financial Outlook	Summary	Q&A

What to Expect?

Bimagrumab	sIBM	Data from pivotal trial and regulatory filing expected
Guselkumab	Psoriasis	Data from 3 pivotal trials and regulatory filing expected
MOR208	DLBCL	■ Phase 2 lenalidomide combo trial to start in Q1 2016 ■ Phase 2 bendamustine combo safety evaluation to start mid 2016 ■ Phase 3 bendamustine combo pivotal study planned for 2017 ■ First data of combination trials in 2017
	CLL	■ Phase 2 idelalisib combo trial to start in Q1 2016 ■ First data of combination trial in 2017
MOR202	MM	Updated data from phase 1/2a trial at ASCO 2016 and ASH 2016
MOR209	Prostate cancer	Continuation of trial under amended protocol, clinical data in 2017
MOR106	Inflammation	Start of phase 1 with Galapagos in H1 2016
MOR107	Fibrosis	Start of phase 1 in Q4 2016
MOR103	RA Osteoarthritis	■ Start of phase 1b/2a in osteoarthritis of the hand ■ Data from the phase 2b in RA in 2017
Pipeline		■ Up to 5 new program starts ■ Around 5 clinical milestones

Content

- Proprietary Pipeline
- Partner Pipeline
- Financial Review 2015
- Financial Outlook
- Summary
- Q&A

Thank You

www.morphosys.com

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-404
Fax +49 (0)89 / 899 27-5404
Email investors@morphosys.com